Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of cancer-related death; however, worldwide incidence and mortality rates do not reflect the geographic variations in the occurrence of this disease. In recent years, increased attention has been focused on the high incidence of esophageal squamous cell carcinoma (ESCC) throughout the eastern corridor of Africa, extending from Ethiopia to South Africa. Nascent investigations are underway at a number of sites throughout the region in an effort to improve our understanding of the etiology behind the high incidence of ESCC in this region. In 2017, these sites established the African Esophageal Cancer Consortium. Here, we summarize the priorities of this newly established consortium: to implement coordinated multisite investigations into etiology and identify targets for primary prevention; to address the impact of the clinical burden of ESCC via capacity building and shared resources in treatment and palliative care; and to heighten awareness of ESCC among physicians, at-risk populations, policy makers, and funding agencies.
Central Hospital and IARC); Lusaka, Zambia (Tropical Gastroenterology and Nutrition Group, University of Zambia); Addis Ababa, Ethiopia (Addis Ababa University and IARC); and Johannesburg and Cape Town, South Africa (University of the Witwatersrand and University of Cape Town). These groups have now joined together in AfrECC (Fig 2) to share expertise, infrastructure, and resources and to ensure that all present and future participant sites in sub-Saharan Africa fully benefit from our collaborative work. During regular conference calls, participants review ongoing activities, identify opportunities and challenges, and plan for the coordination of multisite efforts. In May 2017, AfrECC members convened in East Africa and conducted visits to several AfrECC sites to learn from each other and facilitate closer collaboration. In the future, we aim to establish formal membership guidelines and pursue shared research funding to optimize the impact of our resources and efforts to reduce mortality and suffering from ESCC in this region.

**CURRENT AfrECC PRIORITIES**

Implement Coordinated Multisite Investigations Into the Etiology of ESCC in East Africa and Identify Targets for Primary Prevention

Studies from China and Iran, as well as from the United States, Europe, and Japan, demonstrate considerable etiologic heterogeneity for ESCC, with evidence that major risk factors in one population may play a more limited role in other populations. Whereas etiologic and genetic studies of esophageal cancer in Asian populations have been relatively extensive, the high-incidence region along the eastern corridor of Africa remains largely unstudied. We recently conducted an extensive review to assess whether ESCC risk factors that have been established or are likely in other parts of the world are also present in the African context. Whereas many were identified, most have not been carefully studied in Africa. Moreover, in a number of East African populations, we observed a disproportionate number (approximately 20%) of patients who were diagnosed at younger than 40 years old. This high incidence of ESCC in patients younger...
than 40 years, as well as the geographic variation associated with this diagnosis, suggests plausible roles for unique environmental, infectious, and/or genetic risk factors in this region. Identification of environmental, molecular, and genetic factors, as well as possible interactions, that contribute to the high incidence of this disease along the eastern corridor of Africa will be necessary to inform prevention and early detection strategies in this region.

Case control studies will be a primary method of etiologic research in this setting. A full case control study has completed accrual in Dar es Salaam, Tanzania, and smaller studies from Zambia and Ethiopia have been published. NCI and IARC are supporting several parallel ongoing case control studies at other AfrECC participant sites, collectively known as the ESC-CAPE case control studies. At the three sites that began studies in 2016 and 2017, questionnaires have been harmonized and data are being collected electronically using a mobile health application, which helps standardize the data across sites, allows centralized and remote coordination, and improves real-time quality control. Whereas each individual site has the...
potential to accrue hundreds of patients, no single site is likely to identify the etiologic factors for the development of ESCC throughout the region, and no single study has the potential to confirm associations; thus, multisite collaborations with harmonized study instruments and protocols are needed to allow for comparison and validation of findings. Ultimately, we aim to merge data from multiple study sites to compare and contrast the etiological effects of lifestyle and environmental factors on ESCC across this region. Extensive questionnaire data and saliva and/or blood specimens for future DNA analyses are being collected from all study participants, and multisite genome-wide association studies, such as those previously conducted to investigate this disease in China, are planned.

Case control studies will seek to identify exposures that are implicated in ESCC in Africa; however, many associations will necessarily rely on self-reported data, as biomarker-based assessments are typically not feasible as a result of the severe alteration of the exposure—for example, diet—caused by the disease. Thus, the consortium is also undertaking detailed ecologic and cross-sectional descriptive studies of specific exposures, such as hot beverages and micronutrient deficiencies, to understand major exposure sources, levels, and exposed population groups.

In addition, establishment of ESCC tumor biorepositories for additional genomic profiling is underway. Mutation of the tumor suppressor gene, TP53, has been previously reported as the most frequent genetic alteration in ESCC in other settings, with mutation profiles that are known to vary across geographic areas; however, a recent whole-exome sequencing and RNA sequencing analysis of 59 ESCC tumors from Malawi reported a high proportion of tumors without TP53 mutations, as well as a tumor mutation signature that is possibly consistent with an unknown carcinogenic exposure. This sequencing study from Malawi and case series from South Africa, Zambia, and Kenya have not supported an etiologic role for human papillomavirus and, with rare exception, there is no evidence of an association of ESCC with HIV, either in time trends or in case control data; however, a search for other possible infectious etiologies remains an area of active investigation.

Finally, we recognize that the sustainability and success of our research is ultimately dependent on the efforts of clinical and research colleagues in Africa, and we are committed to the provision of training in research methodology and longitudinal mentoring to enhance and promote cancer research capabilities in the region.

**Address the Impact of the Clinical Burden of Esophageal Cancer Through Capacity Building and Shared Resources in Treatment and Palliative Care**

As in other low- and middle-income countries, patients with ESCC in eastern Africa present with advanced disease with symptoms of dysphagia and obstruction and resultant malnutrition. Patients with ESCC are readily identifiable in surgical and medical hospital wards, profoundly wasted and holding spittoon cups to manage the secretion of saliva. The suffering of these patients is profound and weighs heavily on the minds of the physicians and nurses who care for them, many of whom share sentiments of helplessness and hopelessness because of the lack of available options for early detection, treatment or palliation.
Meanwhile, at Tenwek Hospital, a community-based referral hospital in Bomet, Kenya, where ESCC accounts for 35% of all tumors, surgeons have deployed more than 2,000 self-expanding metal stents (SEMSs) for patients who present with esophageal obstruction. In a review of 1,000 patients who received SEMSs, this technology was demonstrated to be safe and feasible for the palliation of dysphagia symptoms related to ESCC in resource-limited settings; however, at most other sites in eastern Africa, the retail price for imported SEMSs is prohibitive for patients, a barrier that is compounded by the low socioeconomic status and insufficient health insurance of these patients. As a result of financial barriers, the poor distribution of relatively inexpensive SEMSs, and inadequate endoscopy resources and training, palliative stenting is not widely available in eastern Africa. AfrECC is pursuing several options to support advocacy for equal and fair pricing and access to SEMS for the region, as well as capacity-building activities to support endoscopic training, including SEMS placement.

A recent report from China also suggests that steady, incremental progress may eventually yield high-impact programs for ESCC screening and earlier detection, which can significantly reduce mortality. With increased advocacy and awareness about the high incidence of ESCC impacting the region, we anticipate that earlier detection may yield an eventual trend toward increased numbers of patients presenting with tumors that are amenable to curative therapies, including endoscopic therapy, chemoradiation, and/or surgery. We aim to support the development of standardized treatment protocols that are relevant to the available resources within the region. The formation of surgical training partnerships will also facilitate training and the establishment of proficiencies in complex esophagectomy procedures. Finally, implementation strategies are needed to enhance and measure the acceptability, feasibility, and sustainability of each of these interventions, and long-term monitoring is needed to evaluate their effects on clinical outcomes.

Heigten Awareness of ESCC Among physicians, At-Risk Populations, Policy Makers, and Funding Agencies

In the absence of the capacity to provide treatment or palliation for patients with ESCC at most sites throughout eastern Africa, individuals who develop symptoms of dysphagia are commonly reticent to seek care, and there is a pervasive perception that going to the hospital with symptoms of dysphagia means certain death. Sadly, this perception is currently not far from reality, with patients routinely presenting with extremely advanced disease and at risk for rapid deterioration; however, extrapolating from other diseases, increased awareness and education among at-risk populations and physicians may result in earlier presentations for clinical care, earlier diagnosis, and referrals to centers that are equipped to provide the necessary treatment or palliation. In addition, increased advocacy and awareness among local ministries of health and international funding agencies is critical for the provision of resources to increase access to relevant therapies and to support the necessary research to drive the development of evidence-based policies for prevention and palliation. The priority activities of the consortium are summarized in Figure 3.

CONCLUSION

In May 2017, the World Health Assembly endorsed a set of measures to improve and scale up access to prevention, early diagnosis, prompt and accessible treatment, and palliative care for cancer. Member States called on WHO to promote access for all people to affordable cancer diagnosis and treatment and to provide countries with technical guidance to identify and implement priority cancer control interventions. WHO member states committed to ensuring adequate resources to support the implementation of national cancer control plans and to strengthen health systems to provide early diagnosis and treatment services for all patients with cancer. ESCC is one of the most prevalent and deadly cancers that afflicts eastern and southern Africa, and it is certainly one that puts vulnerable populations at risk for great morbidity and catastrophic health expenditures.

The task of scaling up care for ESCC within African health systems that are already fraught with challenges has been dismissed by some as impractical and unattainable because of the deadly nature of this disease. Whereas we acknowledge the challenges, our shared view is that this is the very attribute that makes this work urgent and imperative. We know from the evolution of the HIV epidemic that etiologic understanding, palliation, health system strengthening,
capacity building, and the gradual implementation of effective prevention, early detection, and treatment interventions can provide a path forward, even when faced with the most daunting of diseases.

Although international attention to the tremendous burden of this disease is nascent, there is burgeoning high-quality work in progress at multiple sites in Kenya, Tanzania, Malawi, Zambia, Ethiopia, and South Africa, with the development of etiologic studies, biospecimen repositories, genome-wide association studies, and clinical training partnerships. Looking forward, we aim to enhance the ongoing efforts through increased collaboration across sites and strengthened international partnerships. Our call to action aims to raise awareness of the tremendous impact of this deadly disease on an already fragile region and to mobilize others to become involved.

DOI: https://doi.org/10.1200/JGO.17.00163
Published online on jgo.org on January 25, 2018.

AUTHOR CONTRIBUTIONS
Conception and design: Katherine Van Loon, Michael M. Mwachiro, Christian C. Abnet, Larry Akoko, Steady Chasimpha, Satish Gopal, Bongani Kaimila, Paul Kelly, Maria E. Leon, Christopher G. Mathew, Diana Menya, Yohannie Mlombe, Blandina T. Mmbaga, Elia Mmbaga, Gift Mulima, Beatrice Mushi, Ally Mwanga, Amos Mwasamwaja, M. Iqbal Parker, Joachim Schüz, Russell E. White, Valerie McCormack, Sanford M. Dawsey

Financial support: Christian C. Abnet

Collection and assembly of data: Michael M. Mwachiro, Larry Akoko, Mathewos Assefa, Stephen L. Burgert, Charles Dzamalala, Christopher G. Mathew, Blandina T. Mmbaga, Ally Mwanga, Amos Mwasamwaja, Russell E. White

Data analysis and interpretation: Michael M. Mwachiro, David E. Fleischer, Prasad G. Iyer, Violet Kayamba, Daniel Middleton, Gift Mulima, Gwen Murphy, Ally Mwanga, Amos Mwasamwaja, Natalie Pritchett, Mark D. Topazian, Russell E. White

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Katherine Van Loon
Consulting or Advisory Role: Bayer (Inst)

Michael M. Mwachiro
No relationship to disclose

Christian C. Abnet
No relationship to disclose

Larry Akoko
No relationship to disclose

Mathewos Assefa
No relationship to disclose

Stephen L. Burgert
No relationship to disclose

Steady Chasimpha
No relationship to disclose

Satish Gopal
No relationship to disclose

Research Funding: Intromedic, Exact Sciences, C2 Therapeutics

Consulting or Advisory Role: Medtronic, Symple Surgical

Patents, Royalties, Other Intellectual Property: Capnostics (Inst)

Travel, Accomodations, Expenses: Olympus Keymed

Bongani Kaimila
No relationship to disclose

Violet Kayamba
No relationship to disclose

Paul Kelly
Consulting or Advisory Role: Calibr (Inst)

Maria E. Leon
No relationship to disclose

Christopher G. Mathew
No relationship to disclose

Diana Menya
No relationship to disclose

Daniel Middleton
No relationship to disclose

Yohannie Mlombe
No relationship to disclose

Blandina T. Mmbaga
No relationship to disclose
Elia Mmbaga  
No relationship to disclose  
Gift Mulima  
No relationship to disclose  
Gwen Murphy  
No relationship to disclose  
Beatrice Mushi  
No relationship to disclose  
Ally Mwanga  
No relationship to disclose  
Amos Mwasamwaja  
No relationship to disclose  
M. Iqbal Parker  
No relationship to disclose  
Natalie Pritchett  
No relationship to disclose  
Joachim Schüz  
Employment: Merck KGaA (I)

Mark D. Topazian  
Stock and Other Ownership Interests: Metamodix  
Research Funding: Celgene  
Russell E. White  
No relationship to disclose  
Valerie McCormack  
No relationship to disclose  
Sanford M. Dawsey  
No relationship to disclose

ACKNOWLEDGMENT
We acknowledge the Center for Global Health (CGH) of the National Cancer Institute for its encouragement and its designation of esophageal cancer as a priority disease in sub-Saharan Africa. We thank Matthew Brown of CGH and the Clinton Health Access Initiative for their ongoing partnership in developing a sustainable source for distribution and pricing regulation of self-expanding metal stents in sub-Saharan Africa.

Affiliations
Katherine Van Loon, University of California, San Francisco, San Francisco, CA; Michael M. Mwachiro, Stephen L. Burgert, and Russell E. White, Tenwek Hospital, Bomet; Diana Menya, Moi University, Eldoret, Kenya; Christian C. Abnet, Gwen Murphy, Natalie Pritchett, and Sanford M. Dawsey, National Cancer Institute, Bethesda, MD; Larry Akoko, Elia Mmbaga, Beatrice Mushi, and Ally Mwanga, Muhimbili University of Health and Allied Sciences, Dar es Salaam; Blandina T. Mmbaga and Amos Mwasamwaja, Kilimanjaro Clinical Research Institute, Moshi, Tanzania; Mathewos Assefa, Addis Ababa University, Addis Ababa, Ethiopia; Steady Chasimpha and Charles Dzamalala, Queen Elizabeth Central Hospital; Charles Dzamalala, Satish Gopal, Bongani Kaimila, and Yohannie Mlombe, University of Malawi College of Medicine, Blantyre; Gift Mulima, Kamuzu Central Hospital, Lilongwe, Malawi; David E. Fleischer, Mayo Clinic, Phoenix, AZ; Satish Gopal, University of North Carolina, Chapel Hill, NC; Prasad G. Iyer and Mark D. Topazian, Mayo Clinic, Rochester, MN; Violet Kayamba and Paul Kelly, University of Zambia, Lusaka, Zambia; Paul Kelly, Queen Mary University of London; Christopher G. Mathew, King’s College London, London, United Kingdom; Maria E. Leon, Daniel Middleton, Joachim Schüz, and Valerie McCormack, International Agency for Research on Cancer, Lyon, France; Christopher G. Mathew, University of the Witwatersrand, Johannesburg; and M. Iqbal Parker, University of Cape Town, Cape Town, South Africa.

Support
The African Esophageal Cancer Consortium is supported jointly by the International Agency for Research on Cancer and the Division of Cancer Epidemiology and Genetics of the Intramural Research Program of the National Cancer Institute.

REFERENCES


